Justice Kanor Tetteh, Richard Gyan Aboagye, Addae Boateng Adu-Gyamfi, Seth Christopher Yaw Appiah, Abdul-Aziz Seidu, Frank Lamadoku Attila, Bright Opoku Ahinkorah
Self-reported sexually transmitted infections among men and women in Papua New Guinea: A cross-sectional study
Health science reports
anticoagulants long fundamental preventing treating thromboembolic disorders recent shift focus towards direct oral anticoagulants thanks ease use efficacy safety despite advancements bleeding complications remain major concern anticoagulant highlighting need safer drugs factor xi fxi inhibitors emerged promising agents regard offering novel approach targeting upstream factors coagulation system phase 2 trials shown encouraging outcomes indicating reduced bleeding risk compared traditional anticoagulants particularly context cardiovascular disease management combined antiplatelet therapy however variability findings limited efficacy data call cautious interpretation pending phase 3 trial insights trials essential validating potential fxi inhibitors balance bleeding risk reduction maintain anticoagulant efficacy review explores pharmacology potential indications clinical data future directions fxi inhibitors providing perspective evolving role anticoagulant therapy also provides detailed analysis data published clinical trials fxi inhibitors various indications preliminary data ongoing trials also outlined field moves forward cautiously optimistic outlook expected focusing comprehensive data phase 3 trials define role fxi inhibitors various clinical scenarios